Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Lineage Cell Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- −3 vs. Q1 2024
- Shares held
- 94.4M
- +1.01M (+1.1%) vs. Q1 2024
- Total value
- $94.2M
- −$44.1M (−31.9%) vs. Q1 2024
- New holders
- 8
- 35 more added
- Sold out
- 11
- 26 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Planning Capital Management Corp | 1,100 | $1.10K | 0.00% | +1,000+1,000.0% | Added |
| Crewe Advisors LLC | 1,016 | $1.01K | 0.00% | 00.0% | Unchanged |
| Nisa Investment Advisors, LLC | 636 | $634 | 0.00% | +636 | New |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 300 | $299 | 0.00% | −21−6.5% | Reduced |
| Coppell Advisory Solutions LLC | 63 | $63 | 0.00% | +63 | New |
| Strategic Investment Solutions, Inc. | 44 | $45 | 0.00% | +44 | New |
| Lindbrook Capital, LLC | 29 | $29 | 0.00% | 00.0% | Unchanged |
| National Bank of Canada | 14 | $13 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 5 | $5 | 0.00% | 00.0% | Unchanged |
| St Germain D J Co Inc | 2 | $2 | 0.00% | 00.0% | Unchanged |
| Plante Moran Financial Advisors, LLC | 2 | $2 | 0.00% | 00.0% | Unchanged |
| Lazard Asset Management LLC | 403 | $0 | 0.00% | −5,656−93.3% | Reduced |
| Hantz Financial Services, Inc. | 29 | $0 | 0.00% | 00.0% | Unchanged |
| Wellington Management Group LLP | 0 | $0 | 0.00% | −467,545−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −221,220−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −72,849−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −65,397−100.0% | Sold out |
| Thrivent Financial for Lutherans | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Summit Trail Advisors, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −1,666−100.0% | Sold out |
| BFSG, LLC | 0 | $0 | 0.00% | −355−100.0% | Sold out |
| First Manhattan Co | 0 | $0 | 0.00% | −94−100.0% | Sold out |
| Central Trust Co | 0 | $0 | 0.00% | −29−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −33−100.0% | Sold out |